Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches

Journal of Clinical Pharmacology

Volumn 55, Issue 7, 2015, Pages 757-767

  Small, David S ^a   Ke, Alice Ban ^a   Hall, Stephen D ^a   Mantlo, Nathan ^a   Rotelli, Matthew ^a   Friedrich, Stuart ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

accumulation; half life; physiologically based pharmacokinetics; population pharmacokinetics; volume of distribution

Indexed keywords

ANACETRAPIB; EVACETRAPIB; PLACEBO; BENZODIAZEPINE DERIVATIVE; CHOLESTEROL ESTER TRANSFER PROTEIN; HYPOCHOLESTEROLEMIC AGENT; OXAZOLIDINONE DERIVATIVE;

ARTICLE; COMPARTMENT MODEL; DRUG ACCUMULATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHYSICAL CHEMISTRY; STEADY STATE; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; COMPARATIVE STUDY; HALF LIFE TIME; TIME; VALIDATION STUDY;

ANTICHOLESTEREMIC AGENTS; BENZODIAZEPINES; CHOLESTEROL ESTER TRANSFER PROTEINS; HALF-LIFE; HUMANS; MODELS, BIOLOGICAL; OXAZOLIDINONES; TIME FACTORS;

EID: 84930676254     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.472     Document Type: Article

References (22)

1. Suico JG, Wang MD, Friedrich S, et al., Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults. J Pharm Pharmacol. 2014; 66: 1576-1585.
2. Nicholls SJ, Brewer HB, Kastelein JJ, et al., Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL, LDL cholesterol: a randomized controlled trial. JAMA. 2011; 306: 2099-2109.
3. Health USNIo. ACCELERATE (clinicaltrials. gov NCT01687998). 2014.
4. Bloomfield D, Carlson GL, Sapre A, et al., Efficacy, safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy, coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009; 157: 352-360.
5. Cannon CP, Dansky HM, Davidson M, et al., Design of the DEFINE trial: determining the EFficacy, tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009; 158: 513-519.
6. Gotto AM, Jr., Cannon CP, Li XS, et al., Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014; 113: 76-83.
7. Health NIo. REVEAL (clinical trials. go NCT01252953). 2014.
8. Shinkai H,. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vasc Health Risk Manag. 2012; 8: 323-331.
9. Krishna R, Garg A, Panebianco D, et al., Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol. 2009; 68: 535-545.
10. Dansky HM, Bloomfield D, Gibbons P, et al., Efficacy,safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia. Am Heart J. 2011; 162: 708-716.
11. Friedrich S, Kastelein JJ, James D, et al., The pharmacokinetics and pharmacokinetic/pharmacodynamic relationships of evacetrapib administered as monotherapy or in combination with statins. CPT Pharmacometrics Syst Pharmacol. 2014; 3: e94.
12. Krishna R, Bergman AJ, Green M, Dockendorf MF, Wagner JA, Dykstra K,. Model-based development of anacetrapib a novel cholesteryl ester transfer protein inhibitor. AAPS J. 2011; 13: 179-190.
13. Rowland M, Peck C, Tucker G,. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011; 51: 45-73.
14. Poulin P, Theil FP,. Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J Pharm Sci. 2009; 98: 4941-4961.
15. Lauring B, Li XS, Liu Y, et al., Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib. J Clin Pharmacol. 2014; 54: 1247-1255.
16. Ducharme J, Farinotti R,. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet. 1996; 31: 257-274.
17. FDA. Anti-infective drugs advisory committee meeting: briefing document. TMC207 (bedaquiline) treatment of patients with MDR-TB: NDA 204-384. FDA, MD: FDA, Silver Springs; 2012.
18. Mantlo NB, Escribano A,. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk. J Med Chem. 2014; 57: 1-17.
19. Small DS, Zhang W, Royalty J, et al., Multi-dose study to examine the effect of food on evacetrapib exposure at steady-state. J Cardiovasc Pharmacol Ther. 2015; In press.
20. Rodgers T, Rowland M,. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res. 2007; 24: 918-933.
21. Liu S, Mistry A, Reynolds JM, et al., Crystal structures of cholesteryl ester transfer protein in complex with inhibitors. J Biol Chem. 2012; 287: 37321-37329.
22. Gutstein DE, Krishna R, Johns D, et al., Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clin Pharmacol Ther. 2012; 91: 109-122.